Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BPTF | Q12830 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8114541 | 0.99 | TLR7 (0.43) | TLR7TLR8NUDT1KDM4ENOS3 | |
| SCHEMBL841881 | 0.88 | TLR7 (0.36) | TLR7TLR8NUDT1KDM4ENOS3 | |
| SCHEMBL25575011 | 0.85 | TLR7 (0.46) | TLR7TLR8NUDT1 | |
| SCHEMBL4315485 | 0.83 | TLR7 (0.33) | TLR7NUDT1KDM4ENOS3NOS1 | |
| SCHEMBL24233531 | 0.82 | TLR7 (0.45) | TLR7TLR8NUDT1KDM4EALDH1A1 | |
| SCHEMBL6105335 | 0.82 | KDM4E (0.36) | TLR7NUDT1KDM4ENOS3NOS1 | |
| SCHEMBL7008452 | 0.81 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL1538304 | 0.80 | TLR7 (0.59) | TLR7TLR8NUDT1 | |
| Water SCHEMBL29421423 | 0.79 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| Water SCHEMBL622142 | 0.79 | TLR7 (0.58) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450804-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | claimed |
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-23 | — | — | US | claimed |
| WO-2003045391-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-05 | — | — | WO | claimed |
| EP-0708773-B1 | FUSED CYCLOALKYLIMIDAZOPYRIDINES | MINNESOTA MINING & MFG (US) | 2000-10-04 | — | — | EP | claimed |
| EP-0708773-A1 | FUSED CYCLOALKYLIMIDAZOPYRIDINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| WO-1995002598-A1 | FUSED CYCLOALKYLIMIDAZOPYRIDINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-01-26 | — | — | WO | claimed |
| US-5352784-A | Viricides; immunomodulators | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-10-04 | — | — | US | claimed |
| EP-1651190-B1 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-1450804-B9 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1450804-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-0912564-B1 | PROCESS FOR PREPARING TETRAHYDROIMIDAZOQUINOLINAMINES | MINNESOTA MINING & MFG (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-0708773-B1 | FUSED CYCLOALKYLIMIDAZOPYRIDINES | MINNESOTA MINING & MFG (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-0912564-A1 | PROCESS FOR PREPARING TETRAHYDROIMIDAZOQUINOLINAMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-05-06 | — | — | EP | disclosed |
| US-5693811-A | Process for preparing tetrahdroimidazoquinolinamines | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5648516-A | INTERFERON BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5627281-A | CHEMCAL INTERMEDIATES FOR VIRICIDES BY INDUCING SYNTHESIS OF INTERFERONS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0708773-A1 | FUSED CYCLOALKYLIMIDAZOPYRIDINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| US-5444065-A | Viricides | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-08-22 | — | — | US | disclosed |
| WO-1995002598-A1 | FUSED CYCLOALKYLIMIDAZOPYRIDINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-01-26 | — | — | WO | disclosed |
| US-5352784-A | Viricides; immunomodulators | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | ICOS, STAT6, INMT | TLR7 35/4885TLR8 40/4885NUDT1 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.